Ignite Creation Date:
2024-05-06 @ 7:36 PM
Last Modification Date:
2024-10-26 @ 3:10 PM
Study NCT ID:
NCT06066203
Status:
RECRUITING
Last Update Posted:
2024-01-31
First Post:
2023-09-27
Brief Title:
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin s Lymphoma and Other Hematological Malignancies
Sponsor:
Sichuan Baili Pharmaceutical Co Ltd
Organization:
Sichuan Baili Pharmaceutical Co Ltd
Study Overview
Official Title:
An Open Multicenter Phase I II Clinical Trial to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Antitumor Activity of GNC-035 Tetra-specific Antibody Injection in Relapsed or Refractory Non-Hodgkin s Lymphoma and Other Hematological Malignancies
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I main objectives To observe the safety and preliminary efficacy of GNC-035 in patients with relapsedrefractory non-Hodgkin lymphoma and other hematological malignancies to determine the DLT and MTD or MAD and to determine RP2D Phase II Main objective To explore the efficacy of GNC-035 in patients with relapsedrefractory non-Hodgkin lymphoma and other hematological malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None